Latest / The Onco Life Podcast
FDA Grants Priority Review to Gedatolisib: What This Breakthrough Means for Breast Cancer Treatment
The FDA has granted priority review to gedatolisib, a first-in-class PI3K/mTOR inhibitor for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. In this episode, we explain why this fast-tracked review is such a major milestone—and how it could change treatment options for patients worldwide.You’ll learn:What FDA priority review means and why it matters for cancer patientsHow gedatolisib works and why it’s different from existing breast cancer therapiesWhy HR+/HER2–, PIK3CA wild-type breast cancer has been an unmet treatment needKey results from the Phase 3 VIKTORIA-1 trial…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.